RecruitingRecruiting
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
NCT07783802 · Eli Lilly and Company
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Clazakizumab in Reducing hsCRP in Adults With Elevated hsCRP and Established ASCVD or at Increased Risk for ASCVD Events
About this study
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event.
Participation in the study will last about 9 months.
Eligibility criteria
Inclusion Criteria:
* hsCRP ≥2 mg/L and ≤15 mg/L at screening
* At least one of the following chronic conditions:
* Established atherosclerotic cardiovascular disease (ASCVD)
* Obesity (body mass index (BMI) ≥30 kg/m2)
* Type 2 diabetes
* Hypertension
* Chronic kidney disease Grade 3 or 4
Exclusion Criteria:
* Acute cardiovascular event within 60 days prior to screening
* Acute decompensated heart failure hospitalization within 60 days prior to screening
* Planned coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or major surgery at the time of randomization
* New York Heart Association Class III or IV heart failure
* Uncontrolled hypertension at screening (systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg)
* Type 1 diabetes
* Type 2 diabetes with Hemoglobin A1c ≥9.0% (86 mmol/mol) at screening
* Nephrotic syndrome, estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m², or history of kidney transplant
* Dialysis or acute kidney injury within 60 days prior to screening
* Congenital/hereditary kidney disease, polycystic kidney disease, lupus nephritis, or antineutrophil cytoplasmic antibody-associated vasculitis
* Active tuberculosis, untreated latent tuberculosis, or known hepatitis B or hepatitis C infection
* Serious, opportunistic, chronic, or recurrent infection requiring treatment within 12 weeks prior to screening
* Significant active autoimmune disease
* Suspected or confirmed immunocompromised state (e.g., HIV infection)
* History of peptic ulcer disease or gastrointestinal ulceration within 12 months prior to screening
* History of symptomatic diverticular disease (diverticulitis), gastrointestinal perforation, or major gastrointestinal surgery
* Mechanical heart valve prosthesis requiring chronic vitamin K antagonist anticoagulation
* Use of colchicine within 14 days prior to screening or anticipated need during the study
* Use of immunosuppressive or immunomodulatory agents, including other biologic anti-IL-6 therapies, within specified windows prior to screening
* Use of systemic corticosteroids within 14 days prior to screening
* Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs)
Study design
Enrollment target: 120 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-08-27
Estimated completion: 2027-10
Last updated: 2026-11-03
Interventions
Drug: ClazakizumabDrug: Placebo
Primary outcomes
- • Percent Change from Baseline in hsCRP (Baseline, Week 12)
Sponsor
Eli Lilly and Company · industry
Contacts & investigators
ContactTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · contact · LillyTrials@Lilly.com · 317-615-4559
ContactPhysicians interested in becoming principal investigators please contact · contact · clinical_inquiry_hub@lilly.com
InvestigatorCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · study_director, Eli Lilly and Company
All locations (46)
Heart Center Research, LLCRecruiting
Huntsville, Alabama, United States
Pima HeartRecruiting
Tucson, Arizona, United States
Eclipse Clinical ResearchRecruiting
Tucson, Arizona, United States
Thrive Clinical Research GroupRecruiting
Glendora, California, United States
Omega Research OrlandoRecruiting
Altamonte Springs, Florida, United States
American Research InstituteRecruiting
Cutler Bay, Florida, United States
K2 Medical Research - MaitlandRecruiting
Maitland, Florida, United States
Florida Institute For Clinical Research, LLCRecruiting
Orlando, Florida, United States
North Georgia Clinical ResearchRecruiting
Woodstock, Georgia, United States
Accellacare - DuPageNot Yet Recruiting
Lombard, Illinois, United States
Franciscan Physician Network - Indiana Heart PhysiciansRecruiting
Indianapolis, Indiana, United States
K2 Medical Research - FoxboroughRecruiting
Foxborough, Massachusetts, United States
Revival Research Institute, LLCRecruiting
Dearborn, Michigan, United States
Olive Branch Family Medical CenterRecruiting
Olive Branch, Mississippi, United States
Excel Clinical Research, LLCRecruiting
Las Vegas, Nevada, United States
Palm Research Center TenayaRecruiting
Las Vegas, Nevada, United States
Rochester Clinical Research - BuffaloRecruiting
Buffalo, New York, United States
CHEAR Center LLCRecruiting
The Bronx, New York, United States
Velocity Clinical Research, Cincinnati, SpringdaleRecruiting
Cincinnati, Ohio, United States
Suburban Research AssociatesRecruiting
West Chester, Pennsylvania, United States
Cardiology Consultants of Philadelphia YardleyRecruiting
Yardley, Pennsylvania, United States
Monroe Biomedical Research - CharlestonRecruiting
North Charleston, South Carolina, United States
Horizon Clinical Research GroupRecruiting
Cypress, Texas, United States
Cardiovascular Specialists of WillowbrookRecruiting
Houston, Texas, United States
Texas Cardiology Associates of HoustonRecruiting
Kingwood, Texas, United States
Revival Research Institute, LLCRecruiting
McKinney, Texas, United States
Texas Institute of Cardiology, PARecruiting
McKinney, Texas, United States
Ogden Clinic - Canyon ViewRecruiting
Ogden, Utah, United States
Carient Heart & Vascular - ManassasRecruiting
Manassas, Virginia, United States
Carient Heart and Vascular LLC-RestonRecruiting
Reston, Virginia, United States
CIPRECNot Yet Recruiting
Buenos Aires, Argentina
Cicemo SrlNot Yet Recruiting
Buenos Aires, Argentina
CARDIAMET Investigaciones MédicasNot Yet Recruiting
Buenos Aires, Argentina
Mautalen Salud e InvestigaciónNot Yet Recruiting
Buenos Aires, Argentina
CEMEDICNot Yet Recruiting
Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaNot Yet Recruiting
Buenos Aires, Argentina
Fundación RespirarNot Yet Recruiting
Buenos Aires, Argentina
Instituto Médico Catamarca IMECNot Yet Recruiting
Rosario, Argentina
Centro de Investigaciones Clinicas del LitoralNot Yet Recruiting
Santa Fe, Argentina
Centro de Salud e Investigaciones MédicasNot Yet Recruiting
Santa Rosa, Argentina
Minamino Cardiovascular HospitalNot Yet Recruiting
Hachiōji, Japan
Takai Internal Medicine ClinicRecruiting
Kamakura-shi, Japan
Nakakinen clinicNot Yet Recruiting
Naka, Japan
International University of Health and Welfare Narita HospitalNot Yet Recruiting
Narita, Japan
Dorado Medical ComplexRecruiting
Dorado, Puerto Rico
Wellness clinical Research Vega BajaRecruiting
Vega Baja, Puerto Rico